Articles from DNA Nanobots

DNA Nanobots, a pioneer in self-assembling nanoscale therapeutics, today announced it has secured $3.5 million in funding from a prominent, family office. This significant investment solidifies the company's operational runway for the next 18 months, enabling key advancements in its platform technology.

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced today that Dr. John C. Byrd, M.D., has joined its scientific advisory board (SAB). Byrd is an internationally recognized physician scientist who played significant roles in the translational research and development of several impactful new therapies in blood cell cancers. Byrd has collaborated with DNA Nanobots founding scientists for over 10 years and will continue to help guide the pre-clinical development. Byrd brings the translational expertise to develop DNA Nanobots’ own therapeutic products pipeline and advise on customizable solutions for biopharma partners to improve targeted delivery of therapeutic payloads (see https://dnananobots.com/BPP).

DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, today announced that it completed exclusive commercial licensing of a gene editing technology from the University of California (UC) Berkeley. The licensed intellectual property enables ‘folding’ of genes into their own delivery devices, together with CRISPR-Cas and proximal homology directed repair (HDR) arms for highly efficient non-viral gene delivery.

Destroy Duchenne, a nonprofit organization founded by DMD patient, Elijah Stacy that aims to Complete the CureTM for Duchenne Muscular Dystrophy (DMD), and DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, today announced a partnership to develop new targeted non-viral gene therapy technologies for DMD.

DNA Nanobots, a leader in the design and delivery of DNA nanoparticles engineered for targeted therapeutics, announced today that it has closed its pre-seed funding round. The investment enables DNA Nanobots to launch its BioPharma Partner Program to streamline its end-to-end custom biopharma solutions from design to development for preclinical and animal studies for improved delivery of a wide range of therapeutics. These include small molecules, peptides, antibodies, nucleic acids, and immunotherapies. The amount and names of the experienced biotech angel investors were not disclosed. The company invites BioPharma companies interested in enhancing their drug development pipeline to partner and launched a new portal to start discussions at https://dnananobots.com/BPP.